News Search Results
Apr 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Apr 02, 2026, 10:00 ET Start with Axiom: Clients Choose Axiom as Their First Call for Legal Work
analyze key obligations, and deliver structured reporting to support portfolio management decisions.Brand legal support for a global biotechnology company, serving as strategic advisor and lead counsel across multiple brands and product launches. Embedded with cross-functional teams to
More news about: Axiom Global Inc.
Apr 02, 2026, 08:55 ET INOVIO Announces Pricing of $17.5 Million Public Offering
PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 02, 2026, 08:00 ET Mission BioCapital Announces Opening of $4 Million 2026 Platinum Program Contest and 2025 Platinum Ticket Investments
partners Mission BioCapital, Ono Venture Investment, Alloy Therapeutics, HitGen, Goodwin, and van den Boom & Associates to support high-potential biotechnology innovation around the globe — CAMBRIDGE, Mass., April 2, 2026
More news about: Mission BioCapital
Apr 02, 2026, 08:00 ET GALLO Completes Acquisition of Four Roses Bourbon From Kirin Holdings
Holdings is one of the leading food and beverage manufacturers in Asia and Oceania. Built on more than a century of expertise in fermentation and biotechnology, Kirin delivers a diverse portfolio spanning alcoholic and non-alcoholic beverages, health foods, and pharmaceuticals. With approximately 32,000
More news about: GALLO
Apr 02, 2026, 07:30 ET Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Apr 02, 2026, 07:06 ET VML: World's first T-Rex leather product unveiled - a luxury handbag designed by Enfin Levé
world's first T-Rex leather, creative agency VML (a group company of WPP PLC), genomic engineering leader The Organoid Company, and sustainable biotechnology pioneer Lab-Grown Leather Ltd. - a group company of BSF Enterprise PLC (LSE: BSFA) - have been developing this new material, which will be made
More news about: VML
Apr 02, 2026, 07:00 ET Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis
WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life
More news about: Earendil Labs
Apr 02, 2026, 03:00 ET Lupin Completes Acquisition of VISUfarma
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Apr 02, 2026, 03:00 ET Lupin Completes Acquisition of VISUfarma
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Apr 01, 2026, 20:05 ET INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 01, 2026, 20:00 ET CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
Answer to Uncertainty."About the Gala Dinner Co-HostsWilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company's life cycle — from early-stage intellectual property strategy and
More news about: PharmaDJ
Apr 01, 2026, 16:07 ET ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 01, 2026, 15:59 ET Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents
environment where innovation in CRISPR-enabled research and therapeutics can flourish.About SynthegoSynthego is a pioneering biotechnology company specializing in synthetic biology and genome engineering. Dedicated to providing scientists with the tools, expertise, and support needed
More news about: Synthego
Apr 01, 2026, 11:46 ET Prefilled Syringes Market worth $14.53 billion by 2031 | MarketsandMarkets™
chronic diseases, the demand for prefilled syringes in North America is rising. Further, the presence of numerous pharmaceutical companies and biotechnology firms enhances the growth of the market.Inquire Before Buying@
More news about: MarketsandMarkets
Apr 01, 2026, 11:30 ET FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 01, 2026, 10:29 ET INOVIO to Participate in Upcoming Scientific Conference
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 01, 2026, 10:00 ET PranaX Corporation Appoints Dr. Richard H. LeConey, MD as Chief Medical Officer
HOUSTON, April 1, 2026 /PRNewswire/ -- PranaX Corporation, a biotechnology company focused on regenerative biologics, today announced the appointment of Dr. Richard H. LeConey, MD, as Chief Medical Officer. Dr. LeConey
More news about: PranaX
Apr 01, 2026, 09:09 ET Meeting Client Demand: Tobin Scientific Expands Raw Materials Labeling & Packaging Services
to extend our existing material goods receipt workflows and support improved traceability and operational efficiency for our pharmaceutical and biotechnology clients.
More news about: Tobin Scientific
Apr 01, 2026, 09:00 ET Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
BOSTON, April 1, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced it presented data from the multiple ascending
More news about: Bambusa Therapeutics, Inc.
Apr 01, 2026, 09:00 ET From Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist
be approximately tenfold greater than that of T2DM in China. A Solid Financial Foundation Supporting Long-Term Growth For a biotechnology company in the early stages of commercialization, achieving substantial revenue within the first year of product launch—coupled with an industry-leading
More news about: Innogen
Apr 01, 2026, 08:50 ET Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with
More news about: Anixa Biosciences, Inc.
Apr 01, 2026, 07:35 ET Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Göttingen.In parallel, the Company is progressing its PC111 program through an option agreement to acquire Pincell S.r.l., a clinical-stage biotechnology company. PC111 is a fully human monoclonal antibody targeting pathways involved in inflammation and keratinocyte cell death, with potential applications
More news about: Scinai Immunotherapeutics Ltd.
Apr 01, 2026, 07:00 ET Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Apr 01, 2026, 06:30 ET Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice")
More news about: Immunic, Inc.